NCT06665893Completed
Local Proof of Concept of Evira in Abu Dhabi Study
Evaluating the Efficacy of the Evira Treatment Tool for Childhood Obesity Treatment - a 26- Week Single Arm Interventional Study in Abu Dhabi, United Arab Emirates
Source: ClinicalTrials.gov · Last updated 30 Oct 2024
Brief summary (registry, in English)
Evira is a digital treatment tool developed for treatment of childhood obesity. Through daily weighings at home using a special scale together with a message function in the Evira application, parents and the clinicians can easily follow the child's weight development. The primary aim of this study is to evaluate its efficacy for childhood obesity treatment in Abu Dhabi, with a secondary objective to establish non-inferiority compared to outcomes in a cohort in Stockholm, Sweden.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 70 (actual)
- First submitted
- 29 Oct 2024
- Start date
- 1 Jun 2023
- Primary completion date
- 30 Jun 2024
- Lead sponsor
- Sheikh Shakhbout Medical City
- Diseases
- Obesity
- NCT number
- NCT06665893
What you commit to
- Study type: Interventional
- Participants enrolled: 70
- From 1 Jun 2023 to the primary completion date, 30 Jun 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Treatment for depression and other psychiatric disorders during the last 6 months before inclusion
- Eating disorders requiring therapy during the last six months before inclusion or observed at the inclusion screening.
Other illness
- Endocrine disorders other than well controlled hypothyroidism
- Metabolic disorders of importance for weight control
- Hypothalamic or monogenic obesity, e.g. syndromes and Mb Down
- Severe neuropsychiatric disorders that could affect study compliance
Age
- Morbid obesity defined as iso-BMI\>40 kg/m2 independently of age
Other
- Pharmacological treatment of importance for weight control
Who the study is looking for
- Age \>6.0 and \<16.0 years of age at inclusion
- Obesity according to International Obesity Task Force (IOTF)
- Willingness to participate in an obesity treatment proof of concept trial
- Family ability to communicate e.g. write and read messages in the mobile application
- Parents having a smart phone and an email address
Age in the registry: 6 years to 16 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sheikh Shakhbout Medical City Coordinator of this site? Confirm its status | Abu Dhabi | United Arab Emirates | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.